Using donor-derived DNA and immune cells to predict kidney transplant rejection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to improve the prediction of acute rejection in kidney transplant recipients by analyzing donor-derived cell-free DNA (dd-cfDNA) and regulatory T cells (Tregs). The study will evaluate how levels of dd-cfDNA and specific Treg populations correlate with acute rejection events, particularly focusing on their predictive capabilities for both high and low severity rejections. By identifying these biomarkers, the study seeks to enable non-invasive monitoring of transplant health, potentially leading to timely interventions that could enhance long-term graft survival.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult kidney transplant candidates/recipients

Exclusion Criteria:

* Age less than 18
* Multi-organ transplants
* Kidney transplant candidates/recipients with HIV
* Kidney transplant candidates/recipients with HCV

Where it's running

• Loma Linda University Health
  Loma Linda, California, United States Recruiting

Study contacts

• Principal investigator: Minh-Tri Nguyen, MD PhD — Loma Linda University
• Study coordinator: Ryan Evans, CCRP
• Email: rlevans@llu.edu
• Phone: 9095583870

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Differences in Outcomes After Allograft vs Autograft in Revision ACL Repair

  This study looks at whether using donor tissue (allograft) versus the patient’s own tissue (autograft) in revision ACL surgery leads to different results.

  Recruiting Istituto Ortopedico Rizzoli · Bologna, Bologna · NCT07671235

• Ruxolitinib-enhanced haploidentical transplant for children and young adults with sickle cell disease

  This trial will test whether adding ruxolitinib to a reduced-intensity haploidentical transplant lowers the risk of graft failure in children and young adults with sickle cell disease.

  Recruiting Phase 1/2 Arkansas Children's Hospital Research Institute · Aurora, Colorado and 3 other locations · NCT07252050

• Preventing graft rejection after allogeneic stem cell transplant

  This trial will try the drug emapalumab to see if it can prevent graft rejection in people judged high risk after allogeneic hematopoietic stem cell transplant.

  Recruiting Early Phase 1 Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07244419

• Donor transplant for high risk blood disorders

  This study is testing if a stem cell transplant from a matched sibling can help people with high-risk blood disorders like sickle cell disease and thalassemia feel better.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT06872333

• Investigating graft failure after heart bypass surgery

  This study looks at why heart bypass grafts fail by using special scans and tests on people who have had the surgery and those who might have problems with their grafts.

  Recruiting University of Edinburgh · Edinburgh, Midlothian · NCT06800430

• Comparing immunosuppression strategies in patients with late renal graft failure

  This study is testing whether continuing low-dose immunosuppression or stopping it after six months is better for people with late kidney transplant failure.

  Recruiting Phase 4 Hospital Universitari Vall d'Hebron Research Institute · Barcelona · NCT06676696

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.